Subsidiary to acquire Raghava API business for up to Rs 135 crores via slump sale

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹2565.10

prior close

₹2596.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+3.1% vs market

Pharmaceuticals peers, median of 172sector+0.3%+3.3% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.1

15m

-0.5

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7+0.6+3.1+0.3+3.3

Next day

+6.0+1.3+4.8+0.2+5.8

+3.9+1.7+2.2+0.8+3.1

+11.1+2.2+8.9+1.1+10.0

+9.0+2.1+6.9+0.6+8.4

+8.4+1.9+6.5+0.8+7.6

+8.0-1.3+9.3-1.1+9.1

15d

+19.1+1.3+17.8+0.8+18.3

+13.3-0.8+14.1-2.2+15.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences' wholly owned subsidiary RPG Active Pharma will acquire the API and Intermediates business of Raghava Life Sciences on a slump sale basis for up to Rs 135 crores in cash. The target business earned about Rs 19 crores in FY26 and includes manufacturing and R&D facilities along with a portfolio of 29 API molecules (22 commercialized and 7 under development). The deal is expected to close in about 30 days, subject to regulatory approvals, and is not a related party transaction.

Likely market impact

Strategic expansion of API business through subsidiary; cash outflow up to Rs 135 cr; near-term completion expected within 30 days subject to approvals.